[en] Full text: This study evaluated the safety and efficacy of strontium- 89-chloride in bone metastases patients without bone pain. Methods; an evaluation was made on 54 patients with no painful bone metastases, treated with a single IV dose of 1.48-2.22MBq/kg of strontium-89-chloride. The retreatment was between 3 and 6 months after therapy. Results: The total response rate was 74.0% in 54 patients with no painful bone metastases. The response rate in the focal size>2cm patients was significantly lower than the focal size of 2cm (33.3%? 66.6%, X2=14.9, P<00.1). The side effects of strontium-89-chloride were thrombocytopenia and neutropenia, which were generally mild and reversible. Conclusion: Strontium-89-chloride is effective and safe in painless bone metastases patients. (author)